Diagnostic options · UAE

Tumor Markers tests in Dubai & UAE

Compare available Tumor Markers tests, their listed prices and the information provided for each option. Test selection and preparation should be discussed with your clinician.

Tests in this category

Listed price range

550.00–3,500.00 AED

Clinical preparation

Confirm test-specific instructions with your clinician or laboratory.

Compare available tests

Tumor Markers test prices

Showing 1–14 of 14 matching tests.

Tumor Markers diagnostic tests, details, and listed prices
Test and description	Specimen	Typical duration	Price	Options
TEST-74 5-HIAA (5-Hydroxy Indole Acetic Acid) Random Urine Test This diagnostic test evaluates the level of 5-hydroxyindoleacetic acid (5-HIAA), a metabolite of serotonin, in a random urine sample.	Random Urine	5–7 Working Days	800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["5-Hydroxyindoleacetic acid (5-HIAA)", "Serotonin metabolism"] Parameters [{"name": "5-HIAA", "reference_range": "2–8 mg/24h or 2–8 mg/g creatinine (random)"}] Preparation ["Avoid specific foods (Banana, Kiwi, Walnut, Avocado, Eggplant, Pineapple, Plum, Tomato) for 72 hours.", "Avoid specific medications (Fluorouracil, Melphalan, Paracetamol, Heparin, L-dopa, Reserpine, Salicylates, Chlorpromazine, Imipramine, Isoniazid, MAO Inhibitors, Phenothiazines, Promethazine) for 72 hours.", "Avoid alcohol, caffeine, tobacco, and strenuous exercise for 72 hours.", "Collect a 50 mL random urine sample.", "pH adjusted to 1-2 onsite by phlebotomist."] Indications ["Suspected carcinoid tumor", "Monitoring known carcinoid tumors", "Evaluation of carcinoid syndrome symptoms"] Measurement technique Confirm with laboratory Codes LOINC: 13982-7 ICD-10: C7A.00, E34.0, Z12.8 Clinical summary This diagnostic test evaluates the level of 5-hydroxyindoleacetic acid (5-HIAA), a metabolite of serotonin, in a random urine sample.
TEST-81 5‑HIAA (5‑Hydroxyindoleacetic Acid), 24‑Hour Urine Test This diagnostic test evaluates the level of 5-hydroxyindoleacetic acid (5-HIAA), a metabolite of serotonin, in a 24-hour urine sample.	24-hour urine	5 working days	800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["5-Hydroxyindoleacetic acid (5-HIAA)", "Serotonin metabolism"] Parameters [{"name": "5-Hydroxyindoleacetic acid (5-HIAA)", "reference_range": "< 25 mg/24 h"}] Preparation ["Avoid bananas, avocados, walnuts, pineapple, eggplant, and tomatoes for 48 hours before collection.", "Inform the laboratory of all current medications.", "Do not stop prescribed medications without consulting your physician."] Indications ["Suspected carcinoid syndrome", "Monitoring known carcinoid tumours", "Evaluating neuroendocrine neoplasms"] Measurement technique Confirm with laboratory Codes LOINC: 20568-1 ICD-10: E34.0 Clinical summary This diagnostic test evaluates the level of 5-hydroxyindoleacetic acid (5-HIAA), a metabolite of serotonin, in a 24-hour urine sample.
TEST-450 Breast Monitor Panel Test This diagnostic test evaluates three key tumor markers (CA 15-3, CEA, CA 27.29) in serum to monitor patients with a history of breast cancer for recurrence or response to treatment...	Serum	Daily reporting — results available within 24 hours of sample collection	600.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["CA 15-3", "CEA (Carcinoembryonic Antigen)", "CA 27.29"] Parameters [{"name": "CA 15-3", "reference_range": null}, {"name": "CEA", "reference_range": null}, {"name": "CA 27.29", "reference_range": null}] Preparation ["No special preparation required", "No fasting needed", "No dietary changes needed", "No medication adjustments needed unless instructed by physician"] Indications ["Monitoring for recurrence in patients with a history of breast cancer", "Assessing response to breast cancer therapy", "Longitudinal trend analysis in follow-up care"] Measurement technique Confirm with laboratory Codes LOINC: 24025-5 ICD-10: Z08.0 Clinical summary This diagnostic test evaluates three key tumor markers (CA 15-3, CEA, CA 27.29) in serum to monitor patients with a history of breast cancer for recurrence or response to treatment.
TEST-497 CA 27.29 and CA 15.3 Breast Cancer Markers Panel Test This test measures the levels of two specific tumor markers, CA 27.29 and CA 15.3, in the blood to help monitor patients with known breast cancer.	Serum	2–3 weeks from receipt	1,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["CA 27.29 (Mucin-1 glycoprotein antigen)", "CA 15.3 (Mucin-1 glycoprotein antigen)"] Parameters [{"name": "CA 27.29", "reference_range": null}, {"name": "CA 15.3", "reference_range": null}] Preparation ["No fasting required", "Provide a complete list of current medications and supplements", "Avoid strenuous exercise for 12 hours before collection", "Hydrate normally"] Indications ["Monitoring for recurrence in patients with histologically confirmed breast cancer", "Evaluating therapeutic efficacy in breast cancer patients", "Longitudinal surveillance protocols"] Measurement technique Confirm with laboratory Codes LOINC: 12020-8 ICD-10: C50.9 Clinical summary This test measures the levels of two specific tumor markers, CA 27.29 and CA 15.3, in the blood to help monitor patients with known breast cancer.
TEST-510 Calcitonin Test This diagnostic test evaluates the level of calcitonin hormone in the serum, primarily used as a marker for medullary thyroid carcinoma.	Serum	Same day (sample collected Mon/Thu by 11 AM)	600.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Calcitonin hormone levels", "Parafollicular C-cell activity"] Parameters [{"name": "Calcitonin", "reference_range": null}] Preparation ["Fast for 8–12 hours before the blood draw.", "Inform the clinician about all medications, including proton-pump inhibitors and calcium-channel blockers."] Indications ["Diagnosis of medullary thyroid carcinoma (MTC)", "Screening for multiple endocrine neoplasia type 2 (MEN2)", "Monitoring MTC recurrence"] Measurement technique Confirm with laboratory Codes LOINC: 10489-9 ICD-10: C73 Clinical summary This diagnostic test evaluates the level of calcitonin hormone in the serum, primarily used as a marker for medullary thyroid carcinoma.
TEST-611 Chromogranin A (CGA) Test This diagnostic test evaluates serum levels of Chromogranin A, a protein released by neuroendocrine cells, to aid in the detection and monitoring of neuroendocrine tumors.	Serum or Plasma (EDTA)	Same day (sample received before 11 AM)	1,500.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Chromogranin A protein levels", "Neuroendocrine cell activity"] Parameters [{"name": "Chromogranin A", "reference_range": null}] Preparation ["Temporarily discontinue proton pump inhibitors (e.g., omeprazole) for 14 days prior, under physician supervision.", "Fasting is not required, but follow specific doctor instructions."] Indications ["Diagnosis of neuroendocrine tumors (NETs)", "Monitoring NET progression", "Evaluating response to NET therapy"] Measurement technique Confirm with laboratory Codes LOINC: 104619-7 ICD-10: C7A.00 Clinical summary This diagnostic test evaluates serum levels of Chromogranin A, a protein released by neuroendocrine cells, to aid in the detection and monitoring of neuroendocrine tumors.
TEST-980 Des-Gamma-Carboxy Prothrombin (DCP)/PIVKA-II Serum Test This diagnostic test evaluates levels of abnormal des-gamma-carboxy prothrombin, a protein produced by hepatocellular carcinoma cells.	Serum	Same-day report if sample received by 9 AM	750.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Des-Gamma-Carboxy Prothrombin (DCP)", "PIVKA-II (Protein Induced by Vitamin K Absence or Antagonist-II)"] Parameters [{"name": "Des-Gamma-Carboxy Prothrombin (DCP)", "reference_range": null}] Preparation ["No special fasting required", "Inform phlebotomist of all current medications", "Vitamin K supplements should be withheld for 24 hours prior to collection if medically safe"] Indications ["Detection and monitoring of hepatocellular carcinoma (HCC)", "Complementary testing when AFP is inconclusive", "Screening in high-risk patients (e.g., cirrhosis, chronic hepatitis B/C)"] Measurement technique Confirm with laboratory Codes LOINC: 30501-9 ICD-10: C22.0, Z12.09 Clinical summary This diagnostic test evaluates levels of abnormal des-gamma-carboxy prothrombin, a protein produced by hepatocellular carcinoma cells.
TEST-1124 Fibroblast Growth Factor (FGF2) Assay Test This test quantifies basic Fibroblast Growth Factor (FGF2) in plasma to assess angiogenesis and monitor tumour progression.	Plasma (Peripheral Blood)	2–3 Weeks (Monthly batch collection by 7th of month)	3,500.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Basic Fibroblast Growth Factor (FGF2)", "Angiogenic activity", "Tumour vascularisation"] Parameters [{"name": "Fibroblast Growth Factor (FGF2)", "reference_range": null}] Preparation ["A duly completed Send Out Consent Form (Form 35) is mandatory prior to collection."] Indications ["Oncology care plan management", "Monitoring anti-angiogenic therapy", "Assessing treatment resistance signals", "Gastroenterology diagnostics", "Longevity medicine assessment"] Measurement technique Confirm with laboratory Codes LOINC: 21253-5 ICD-10: R97.8 Clinical summary This test quantifies basic Fibroblast Growth Factor (FGF2) in plasma to assess angiogenesis and monitor tumour progression.
TEST-1375 HE4 (Human Epididymis Protein 4) Test This diagnostic test evaluates the level of Human Epididymis Protein 4 (HE4) in the serum, aiding in the assessment of ovarian cancer risk.	Serum	Same-day reporting for samples received by 4 PM Monday and Thursday	550.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["HE4 protein levels in serum"] Parameters [{"name": "HE4 Test", "reference_range": "< 150 pmol/L (Reference ranges may vary)"}] Preparation ["No special preparation is required", "Fasting is not necessary", "Continue taking all prescribed medications", "Inform the phlebotomist of any anticoagulant therapy"] Indications ["Risk stratification of epithelial ovarian cancer", "Monitoring of epithelial ovarian cancer", "Evaluation in conjunction with CA-125 and ROMA algorithm"] Measurement technique Confirm with laboratory Codes LOINC: 47213-1 ICD-10: Z12.73 Clinical summary This diagnostic test evaluates the level of Human Epididymis Protein 4 (HE4) in the serum, aiding in the assessment of ovarian cancer risk.
TEST-1500 Hepatocellular Carcinoma (HCC) Panel Test This test evaluates three key biomarkers (AFP, PIVKA-II, Glypican-3) to aid in the early detection and surveillance of hepatocellular carcinoma (liver cancer).	Blood (Serum/Plasma)	Same-day report (sample received by 9 AM)	950.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Alpha-Fetoprotein (AFP)", "Protein Induced by Vitamin K Absence‑II (PIVKA‑II)", "Glypican‑3"] Parameters [{"name": "Alpha-Fetoprotein (AFP)", "reference_range": null}, {"name": "Protein Induced by Vitamin K Absence‑II (PIVKA‑II)", "reference_range": null}, {"name": "Glypican‑3", "reference_range": null}] Preparation ["No fasting required", "Provide brief clinical history including known liver disease, current medications, and recent imaging results"] Indications ["Surveillance for hepatocellular carcinoma in high-risk populations", "Patients with chronic hepatitis B/C", "Patients with cirrhosis"] Measurement technique Confirm with laboratory Codes LOINC: 1834-1 ICD-10: C22.0 Clinical summary This test evaluates three key biomarkers (AFP, PIVKA-II, Glypican-3) to aid in the early detection and surveillance of hepatocellular carcinoma (liver cancer).
TEST-2662 Neuron Specific Enolase (NSE) Serum Test This test measures the level of Neuron Specific Enolase (NSE) in the serum to aid in the monitoring of neuroendocrine tumors and certain neurological conditions.	Serum	Same business day (samples collected by 11:00 AM)	800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Neuron Specific Enolase (NSE)", "Glycolytic enzyme enolase (gamma-gamma dimer)"] Parameters [{"name": "Neuron Specific Enolase (NSE)", "reference_range": null}] Preparation ["No fasting required.", "Inform phlebotomist if taking anticoagulants or have bleeding disorders.", "Inform phlebotomist of recent illnesses, vaccinations, or trauma."] Indications ["Monitoring neuroendocrine tumors (e.g., SCLC, Neuroblastoma)", "Assessing therapeutic response", "Determining prognosis"] Measurement technique Confirm with laboratory Codes LOINC: 1742-6 ICD-10: C7A.9 Clinical summary This test measures the level of Neuron Specific Enolase (NSE) in the serum to aid in the monitoring of neuroendocrine tumors and certain neurological conditions.
TEST-2819 Ovarian Cancer Panel Test This diagnostic test evaluates key tumour biomarkers (CA-125, HE4) and calculates the ROMA index to assess the risk of ovarian malignancy.	Blood (Serum/Plasma)	Same-day reporting (samples received by 9:00 AM)	650.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["CA-125", "HE4", "ROMA Index"] Parameters [{"name": "CA-125", "reference_range": null}, {"name": "HE4", "reference_range": null}, {"name": "ROMA Index", "reference_range": null}] Preparation ["No fasting or special preparation is required", "Avoid high-dose biotin supplements for 24 hours prior to sampling", "Continue all prescribed medications unless advised otherwise by your physician"] Indications ["Evaluation of pelvic masses", "Risk assessment for ovarian cancer", "Monitoring response to ovarian cancer treatment"] Measurement technique Confirm with laboratory Codes LOINC: 10383-7 ICD-10: C56, Z12.73 Clinical summary This diagnostic test evaluates key tumour biomarkers (CA-125, HE4) and calculates the ROMA index to assess the risk of ovarian malignancy.
TEST-2975 Prostate Health Index (PHI) Test The PHI test evaluates the risk of clinically significant prostate cancer by analyzing specific PSA isoforms in the blood.	Serum (Peripheral Blood)	Same Day (Samples received Mon–Fri by 4 PM)	800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Total PSA", "Free PSA", "[-2]proPSA (p2PSA)"] Parameters [{"name": "Total PSA", "reference_range": null}, {"name": "Free PSA", "reference_range": null}, {"name": "[-2]proPSA (p2PSA)", "reference_range": null}, {"name": "PHI Score", "reference_range": null}] Preparation ["Avoid ejaculation for 48 hours prior to the test.", "Inform physician about all medications, especially 5-alpha-reductase inhibitors.", "Schedule blood draw at least 7 days after DRE or prostate massage."] Indications ["Risk stratification for prostate cancer", "Evaluation of men with elevated PSA levels", "Decision support before prostate biopsy"] Measurement technique Confirm with laboratory Codes LOINC: 89381-8 ICD-10: Z12.5 Clinical summary The PHI test evaluates the risk of clinically significant prostate cancer by analyzing specific PSA isoforms in the blood.
TEST-3064 ROMA (Risk of Ovarian Malignancy Algorithm) Test The ROMA test evaluates the probability of ovarian malignancy in women with a pelvic mass by combining CA125, HE4, and menopausal status.	Serum or Plasma	Same-day (sample collected Mon/Thu before 4 PM)	750.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Serum CA125 levels", "Serum HE4 levels", "Menopausal status"] Parameters [{"name": "CA125", "reference_range": null}, {"name": "HE4", "reference_range": null}, {"name": "ROMA Score", "reference_range": null}] Preparation ["Menopausal status must be known", "No specific fasting required"] Indications ["Evaluation of adnexal masses in premenopausal women", "Evaluation of adnexal masses in postmenopausal women", "Risk stratification for epithelial ovarian cancer"] Measurement technique Confirm with laboratory Codes LOINC: 77399-3 ICD-10: R97.6 Clinical summary The ROMA test evaluates the probability of ovarian malignancy in women with a pelvic mass by combining CA125, HE4, and menopausal status.

Category overview

Tumor Markers: overview

Navigating a cancer diagnosis or monitoring your remission journey can be incredibly emotional, but having precise biological data provides a clear, empowering path forward. As a critical component of our advanced Biochemistry services, precise Tumor Markers testing evaluates specific proteins and antigens associated with cellular changes. Utilizing cutting-edge diagnostic technology, this specialized oncological screening helps your medical team monitor treatment efficacy and safely guide personalized, proactive care. Recognized for excellence among diagnostic labs in Dubai and the UAE, DNA Labs ensures strict patient confidentiality, uncompromising diagnostic accuracy, and rapid reporting for sensitive results. Take control of your health journey—book your tumor markers testing in UAE, schedule a comfortable home sample collection, or consult our specialized team today.

Before booking

Use the test details as a conversation starter

The right diagnostic option depends on your reason for testing and individual circumstances. Check the listed specimen and timing, then confirm any preparation requirements with the ordering clinician or laboratory before collection.